ETHYL 2-CYANO-3-OXOCYCLOPENTANECARBOXYLATE, 95.0%, 250mg

6-Bromooxazolo[4,5-b]pyridine, 95.0%, 1g

1,2,3,4-Tetrahydro-6-methylquinoline, 98.0%, 5g

alpha,alpha'-Bis(4-methylbenzyloxy)-p-xylene>98.0%(GC)1g

3-Butynoic acid, 98.0%, 5g

(R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide hydrochloride, 95.0%, 250mg

Filtrationsgeräte mit PES-Membran, Ø 50 mm, Porengröße 0,45 µm, 150 ml, 12 Stück

6-[(4-Nitrobenzyl)thio]-9-beta-D-ribofuranosylpurine, 98.0%, 250mg

4-Bromo-alpha-methylbenzyl alcohol, 97.0%, 5g

2-Amino-5-methylpyrimidine-4,6(1H,5H)-dione, 95.0%, 1g

4-(Trifluoromethyl)benzyl Alcohol>96.0%(GC)25g

Linsitinib, 250mg

(S)-2-Amino-3-(2-chlorophenyl)propanoic acid, 95.0%, 25g